TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Depression and anxiety score changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the curve of absorption of vitamin E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of change of the right distal common carotid artery far wall intima-media thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: flow mediated brachial artery vasoactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Binding potential in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oropharyngeal Leak Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of complete regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor-related deaths
Endpoint domain: Mortality/survival
Primary endpoint: Average number of steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of steps after Pokemon Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with death
Endpoint domain: Mortality/survival
Primary endpoint: Number of budesonide/formoterol use per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in HAM-D (17)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain score during hysterosalpigography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matching number of steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete healing of the wound (reepithelization)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Kinematic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cardiometabolic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Perceived Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Peripheral Artery Disease Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual analogue Scale (VAS) for general complaints and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device Retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from Baseline in insulin sensitivity (SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in total energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in beta-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline in disposition index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in the Raynaud's Condition Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: speech reception threshold (SRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Without Excessive Bleeding at Surgical Sites and Did Not Require BPA/FVIII Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Excessive Bleeding at Surgical Sites and Required BPA/FVIII Use
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Surgical Complications Requiring Hospitalization or Return to Surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Seroprevalence of IgM and IgG against Nucleocapsid of SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprevalence of IgM and IgG against spike-receptor binding domain of SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in voiding diary variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pap smear results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Major Adverse Cardiac Event (MACE) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Patients That Complete the Protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: KOOS Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Genotyping for SNP associated with primary open angle glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence and Severity of AEs and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with VF at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Digit-Span Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Gut fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Protein and lipid changes in immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biomarkers of vitamin A, iron, and zinc status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1-year freedom from recurrence of TR≥3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year freedom from progression by 2 degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Dose Limiting Toxicity (DLT) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Meeting Feasibility Requirements
Endpoint domain: Resource use
Primary endpoint: Dose-normalized Trough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gambling Problems Index (GPI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IBS Symptom Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBD Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of oxaliplatin-paclitaxel combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Doppler-based renal resistive index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Combined endpoint of arrhythmias, myocardial infarction, stroke, low-output syndrome, cardiogenic shock, and death
Endpoint domain: Mortality/survival
Primary endpoint: Heart rate less than 80 BPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen saturation less than 80%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plantar pressure of region of interest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Berg balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in creatine kinase (CK) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Short Form McGill Questionnaire total scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Changes in VAS pain ratings
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Effectiveness of NESP in treating anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life after Brain Injury
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants with Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), or Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serum Antibody (Ab) Levels that Meet or Exceed the Threshold of Protection From COVID-19
Endpoint domain: Physiological/clinical
Primary endpoint: Geometric Mean (GM) Value of the Serum Ab Level
Endpoint domain: Physiological/clinical
Primary endpoint: VTE events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum biomarkers in neuron derived extracellular vesicles (NDEVs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sensitivity of dielectric property test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: specificity of dielectric property test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent change in lumbar spine (L1-4) bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in sexual functioning
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: static 2-point discrimination (2PD) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma AUC[0-tau]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bath Ankylosing Spondylitis Functional Index (BASFI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ankylosing Spondylitis Quality of Life (ASQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Successful Eradication of H. Pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of subjects with treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with clinically-significant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Inhibition of Platelet Aggregation Final Extent at 2 Hours Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of Platelet Aggregation Final Extent at 4 Hours Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of Platelet Aggregation Final Extent at 8 Hours Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of Platelet Aggregation Final Extent at 12 Hours Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of Platelet Aggregation Final Extent at 24 Hours Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Prostate Specific Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Syndrome Scale-Excitatory Subscale (PANSS-EC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuromuscular responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of DI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of DI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 meters walking test (gait speed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central venous saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Invasive Disease-free Survival (IDFS) Event
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Invasive Disease-free Survival (IDFS) Events
Endpoint domain: Mortality/survival
Primary endpoint: Long term efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Interleukin (IL)-6 level of GCF at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline IL-8 level of GCF at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline IL-10 level of GCF at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Radiation dose adsorbed by operators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia Outcome and Severity Scale Score (DOSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Curve (AUC) of liraglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration [Cmax] of NR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration [Cmax] of pterostilbene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve [AUC] of NR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve [AUC] of pterostilbene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Emergent Laboratory Abnormalities (Safety)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Nutrition Literacy Assessment Instrument (NLit) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Differentiation of Bifidobacterium levels in infant stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of new vehicle formulations
Endpoint domain: Adverse events/effects
Primary endpoint: Oral Feeding Difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of potential biomarkers in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentrations of potential biomarkers in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of naproxen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of naproxen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Intracranial Objective Response Rate (iORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior changes regarding physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of laboratory confirmed cases of Influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of complete remissions (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurovascular Complexity Index (NCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Normalized melatonin rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P (a-ET) CO2 gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clinical response of vasculitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Free of Disease-progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: QRS morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CSF and serum biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in trough Forced expiratory volume in one second (FEV1) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in Mahler Transitional Dyspnoea Index (TDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change on height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with middle ear effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: Proportion of study visits at which middle ear effusion detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: Number of fibrotic left ventricular segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Surfactant therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SpO2 at 5th minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SpO2 at 10th minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in student knowledge of contraceptive methods
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quit Rate at 1 month
Endpoint domain: Mortality/survival
Primary endpoint: Quit Rate at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Plasma Concentration (Cmax) of Ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t) of Ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of CTCs in the blood drawn from central line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of CTCs in the blood drawn from peripheral line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Achieved a Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hemoglobin a1c (percent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in systolic blood pressure (mmhg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in diastolic blood pressure (mmhg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in weight (pounds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of telephone-based health coaching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Craving and withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication of Ureaplasma urealyticum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change from baseline fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report WTC-related PTSD Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinician Rated WTC-related PTSD Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Who Had One or More Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had One or More Serious ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had One or More Hypoglycemia of Serious ADRs and the Other ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had One or More Infection of Serious ADRs and the Other ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Communities With C. Trachomatis Infection Prevalence of 1% or Below
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lesions diagnosed via wide-field fluorescence imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesions diagnosed via point spectroscopy system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesions diagnosed via non-invasive brush cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readiness to be released from the PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Responses to Affective Touch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes